Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Bryan S Walsh"'
Publikováno v:
Journal of Clinical Oncology. 40:1102-1110
PURPOSE Generic competition can be delayed if brand-name manufacturers obtain additional patents on supplemental uses. The US Food and Drug Administration allows generic drug manufacturers to market versions with skinny labels that exclude patent-pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38aed91c3d85304a6ca4180a7a366513
https://doi.org/10.1200/jco.21.02139
https://doi.org/10.1200/jco.21.02139
Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes
Publikováno v:
Nature Biotechnology. 40:167-169
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae991c5ff8be84303b5197ff7b269efa
https://doi.org/10.1038/s41587-021-01204-y
https://doi.org/10.1038/s41587-021-01204-y
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Antiretroviral (ARV) medications to treat HIV are a major contributor to Medicaid prescription drug spending. Despite having been used for over 2 decades, the first generic ARVs only recently became available, and many newer versions continue to be s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3b290f886681e2aee0d5c2cfeaf33f71
https://pubmed.ncbi.nlm.nih.gov/36268585
https://pubmed.ncbi.nlm.nih.gov/36268585
Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes
Publikováno v:
Nature biotechnology. 40(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d975f6f9ffa22be1afe1a1e378f35f13
https://pubmed.ncbi.nlm.nih.gov/35169305
https://pubmed.ncbi.nlm.nih.gov/35169305
Publikováno v:
JAMA. 326(14)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5773e0216d022a9d0700f6680580048
https://pubmed.ncbi.nlm.nih.gov/34515733
https://pubmed.ncbi.nlm.nih.gov/34515733
Autor:
Aaron S. Kesselheim, Bryan S Walsh
Publikováno v:
The American journal of managed care. 27(8)
In response to brand-name drug manufacturers developing co-pay assistance programs to help patients pay high out-of-pocket costs for expensive brand-name drugs, insurers have developed co-pay accumulator adjustment programs (CAAPs) that exclude payme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::138d41a18fd91af6cfb1760d9221f58f
https://pubmed.ncbi.nlm.nih.gov/34460172
https://pubmed.ncbi.nlm.nih.gov/34460172
Publikováno v:
JAMA Intern Med
This cohort study assessed the frequency of approvals of first generic drugs with skinny labels in the US.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78445ac9c476e5273d638d66b546b41
https://pubmed.ncbi.nlm.nih.gov/33779681
https://pubmed.ncbi.nlm.nih.gov/33779681
Publikováno v:
JAMA Internal Medicine. 182:245
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9921292c9a38f722711a8de6a9c7dc7e
https://doi.org/10.1001/jamainternmed.2021.7954
https://doi.org/10.1001/jamainternmed.2021.7954